Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: Grainne who wrote (1192)	4/24/1998 11:20:00 PM
From: muddphudd	Respond to of 1359

FYI: Genentech/Idec Rituxan (Rituximab) Sales Total $43.2 Million Since Launch in late 1997; Rituxan growth offsets declining sales for Pulmozyme (dornase alfa), Activase (alteplase), and growth hormone line. Activase is being negatively affected by two large Phase III programs for thrombolytic agents (Bristol's lanoteplase with 15,000 patients; and Genentech's own second generation product with Boehringer-Ingelheim TNK-TPA with 16,500 patients). I got this off of: fdcreports.com.